Oncardia Cardiology Imaging

99mTc-Oncardia is the first target specific functional imaging agent developed for use with SPECT cameras to diagnose the presence and extent of myocardial ischemia in patients with confirmed coronary artery disease. Unlike current nuclear cardiology imaging, referred to as MPI imaging, which images blood flow and most often requires a rest and stress imaging study, Oncardia targets the damaged region of the heart without the need to require the patient to undergo a stress study. The imaging study is completed in approximately 30 minutes post injection. When the manufacture of new Oncardia kits is completed, Cell Theranostics will resume the Phase 2b/3 trial for cardiac ischemia imaging.

Past, Current and Future Clinical Trial Sites:

Have Questions?

Frequently Asked

Read All FAQs